Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 129   

Articles published

NVO 56.48 -0.64 (-1.12%)
price chart
McDonald's Corporation (MCD), Novo Nordisk A/S (ADR) (NVO), Colgate ...
Another major hedge fund that recently disclosed its long equity positions for the second quarter of 2014 is Jim Simons' Renaissance Technologies, one of the best performing firms in the sector.
Novo Nordisk (NVO) Wins FDA Nod For Weight-Loss Injection
Novo Nordisk A/S (ADR) (NYSE:NVO) announced Wednesday that the US Food and Drug Administration (FDA) has approved its experimental weight-loss injection, Saxenda, to treat obesity in adults.
Related articles »  
Sanofi Still Ahead Of Novo Nordisk In Insulin Drug Race
Novo Nordisk A/S (ADR) (NVO) announced yesterday, that its insulin therapy Tresiba, which was in late-stage trials, has proved to be safe and effective for the treatment of type 1 diabetes in children and young adults.
Related articles »  
Novo Nordisk And Eli Lilly Battling To Win GLP-1 Drug Market
Diabetes patients have a multitude of therapy options available, ranging from tablets and insulin therapies to the less common glucagon-like peptide-1 (GLP-1) agonists.
Related articles »  
Sanofi And Novo Nordisk's Basal-Insulin Battle Continues
Sanofi SA (ADR) (SNY) and Novo Nordisk A/S (ADR) (NVO) are the two main players in the ongoing race for developing effective basal insulin therapies for the treatment of diabetes.
Related articles »  
Trending Stocks: Novo Nordisk A/S (ADR) (NVO), Actavis plc (ACT), CVS Health ...
Novo Nordisk A/S (ADR) (NYSE:NVO) increased 1.58% and closed at $57.16 in the last trading session with the overall traded volume of 939,976 shares, versus the average volume of 2.01 million shares.
Novo Nordisk A/S (ADR) (NVO): A Company Solving The Global Diabetes Crisis ...
Novo Nordisk A/S (NYSE: NVO) is the undisputed global leader in the diabetes market. The company's impressive product portfolio is home to five of the world's 10 best-selling diabetes medications.
Related articles »  
Novo Nordisk's (NVO) Diabetes Drug Victoza Receives Positive Review By CHMP
Novo Nordisk A/S (ADR) (NYSE:NVO) announced Friday that its key drug Victoza has received positive reviews from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for the treatment of type 2 diabetes ...
Related articles »  
Is Novo Nordisk A/S (ADR) (NVO) Going to Burn These Hedge Funds?
In the 21st century investor's toolkit, there are a multitude of metrics investors can use to track Mr. Market. A couple of the most under-the-radar are hedge fund and insider trading movement.
Related articles »  
Stocks with Downward Movements: Lam Research (LRCX), Novo Nordisk A/S ...
Novo Nordisk A/S (ADR) (NYSE:NVO) moved down -0.28% with the closing price of $56.21. The overall volume in the last trading session was 1.39 million shares.